Disposition of tradable shares by Jenne Kyle of Ionis Pharmaceuticals subject to Rule 16b-3
| IONS Stock | USD 35.90 0.53 1.50% |
Slightly above 50% of Ionis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Ionis Pharmaceuticals stock suggests that some investors are interested at this time. Ionis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Ionis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Ionis |
Filed transaction by Ionis Pharmaceuticals Officer Evp, Chf Gl Pdt Str Ofcr. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Ionis Pharmaceuticals Fundamental Analysis
We analyze Ionis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Ionis Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Ionis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ionis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ionis Pharmaceuticals Related Equities
| ARWR | Arrowhead Pharmaceuticals | 24.23 | ||||
| TERN | Terns Pharmaceuticals | 7.82 | ||||
| SRPT | Sarepta Therapeutics | 5.70 | ||||
| APLS | Apellis Pharmaceuticals | 4.63 | ||||
| AKRO | Akero Therapeutics | 3.24 | ||||
| IOVA | Iovance Biotherapeutics | 3.07 | ||||
| VKTX | Viking Therapeutics | 2.04 | ||||
| HALO | Halozyme Therapeutics | 1.42 | ||||
| INCY | Incyte | 0.87 | ||||
| BMRN | Biomarin Pharmaceutical | 0.83 | ||||
| KRYS | Krystal Biotech | 0.20 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.15 | ||||
| EXEL | Exelixis | 1.43 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
| PTCT | PTC Therapeutics | 1.96 |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.